Raws li xyoo 2016 WHO kev faib tawm, kev kuaj mob ntawm erythroid leukemia ntshiab yuav tsum muaj cov hauv qab no [3,12 : >80% tsis paub qab hau erythroid precursors nrog ≥30% proerythroblasts. < 20% myeloblasts. Tsis muaj kev kho ua ntej.
Pure erythroid leukemia yog dab tsi?
Ntshiab erythroid leukemia (PEL), ib qho tsis tshua muaj hematological malignancy, txhais tau tias yog muaj >80% ntawm proliferating erythroblasts ntawm tag nrho cov nucleated pob txha hlwb. Raws li kev faib tawm los ntawm Lub Koom Haum Saib Xyuas Kev Noj Qab Haus Huv Ntiaj Teb hauv xyoo 2008, PEL raug cais raws li mob ntshav qab zib mellitus (AML) tsis tau teev tseg.
WHO faib AML 2018?
Qhov kev faib tawm tshiab ntawm WHO yog raws li hauv qab no: AML nrog cov caj ces txawv txav: AML nrog t(8; 21)(q22; q22), (AML1 / ETO); AML nrog cov pob txha txawv txav eosinophils thiab inv(16)(p13q22) lossis t(16;16)(p13)(q22), (CBFB/MYH11); APL nrog PML/RARa; AML nrog t(9;11)(p21. 3;q23.
CML kev faib tawm yog leej twg?
mob myeloid neoplasms nyob rau hauv lem muab faib ua plaub pawg ua haujlwm: myelodysplastic syndromes(MDS), MPNs, MDS / MPN sib tshooj thiab myeloid / lymphoid neoplasms nrog eosinophilia thiab rov ua dua tshiab ntawm PDGFRA, PDGFRB, thiab FGFR1 lossis PMC1-JAK2; cov kev hloov tom kawg sib raug rau 5q33, 4q12, 8p11.
Koj kho Erythroleukemia li cas?
Kev kho mob. Kev kho mob rauerythroleukemia feem ntau ua raws li rau lwm hom AML, tsis tau teev tseg. Nws muaj kws khomob, nquag muaj cytarabine, daunorubicin, thiab idarubicin. Nws tseem tuaj yeem koom nrog kev hloov pob txha pob txha.
